Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea

Abstract

The long-term efficacy of IFX in a large, real-life cohort of Korean UC patients appears to be comparable to that in previously published Western studies.

Long‐term efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

“…This may be because the number of 5‐year follow‐up patients with efficacy data was too small to determine the 5‐year clinical response and remission rates accurately. However, the 5‐year retention rate of CT‐P13 without disease worsening in our study appeared to be similar to that in previous studies reporting a 5‐year probability of maintaining infliximab with sustained clinical benefit of 49–63% in CD and 27–45% in UC patients . Our study suggests that treatment of IBD with CT‐P13 was effective for long‐term maintenance therapy as well as induction therapy.…”

“…However, the 5-year retention rate of CT-P13 without disease worsening in our study appeared to be similar to that in previous studies reporting a 5-year probability of maintaining infliximab with sustained clinical benefit of 49-63% in CD and 27-45% in UC patients. 5,[28][29][30][31] Our study suggests that treatment of IBD with CT-P13 was effective for long-term maintenance therapy as well as induction therapy. In addition, the efficacy of CT-P13 seems to be not inferior to that of infliximab.…”

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis

“…Several studies have described the long-term efficacy of IFX in East Asian population with UC; however, these studies were heterogeneous in their designs and patient popula-tions. [13][14][15]30,31 Large prospective studies with standardized protocols in different Asian populations with ASUC are therefore needed to overcome these limitations. Further clinical trials with different biologics or small molecules are also needed in this setting.…”

“…12 We found several studies reporting on the efficacy and safety of IFX treatment in East Asian populations, including in Korea and Japan; however, specific data in subsets of hospitalized patients with ASUC were severely limited. [13][14][15] In this context, we established a unique multicenter cohort of hospitalized patients with ASUC, who satisfied the criteria given by Truelove and Witts 3 and were treated with IVCS or IFX during index hospitalization. The specific aims of our study were (1) to investigate the therapeutic outcomes of IFX treatment in a long-term setting and (2) to identify predictive factors for colectomy in our study cohort, as well as in a subset of patients who received IFX.…”

Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis

“…IFX was superior to placebo in achieving clinical remission and response, mucosal healing, and colectomy-free survival in patients with moderate-to-severe active UC. [ 10 , 11 ] It is, however, also associated with potentially severe adverse events, such as infusion reactions and infections.…”